HC Wainwright Issues Positive Forecast for Atossa Genetics (NASDAQ:ATOS) Stock Price

Atossa Genetics (NASDAQ:ATOS) had its price objective hoisted by equities researchers at HC Wainwright from $7.00 to $25.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 361.25% from the company’s current price.

A number of other equities research analysts have also recently commented on the stock. Ascendiant Capital Markets lifted their price target on shares of Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $68.33.

Atossa Genetics Stock Performance

Shares of ATOS opened at $5.42 on Thursday. The firm has a market capitalization of $46.67 million, a P/E ratio of -1.51 and a beta of 1.42. Atossa Genetics has a 52 week low of $3.76 and a 52 week high of $19.35. The stock has a 50 day moving average price of $5.88 and a two-hundred day moving average price of $10.02.

Atossa Genetics (NASDAQ:ATOS) last posted its earnings results on Wednesday, March 25th. The company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.29). On average, equities analysts forecast that Atossa Genetics will post -0.22 earnings per share for the current year.

Institutional Investors Weigh In On Atossa Genetics

Institutional investors and hedge funds have recently modified their holdings of the company. XTX Topco Ltd increased its holdings in Atossa Genetics by 581.2% during the 4th quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after acquiring an additional 144,412 shares during the period. &PARTNERS purchased a new position in shares of Atossa Genetics during the 4th quarter valued at $25,000. Graham Capital Management L.P. grew its position in shares of Atossa Genetics by 27.8% during the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock valued at $125,000 after purchasing an additional 45,923 shares in the last quarter. State Street Corp increased its holdings in shares of Atossa Genetics by 31.2% in the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock worth $352,000 after purchasing an additional 141,990 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after buying an additional 514,175 shares in the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.